Maternal exposure to statins and risk for birth defects: A case-series approach

American Journal of Medical Genetics, Part A

Volumn 146, Issue 20, 2008, Pages 2701-2705

  Petersen, Emily E ^a,b   Mitchell, Allen A ^c   Carey, John C ^d   Werler, Martha M ^c   Louik, Carol ^c   Rasmussen, Sonja A ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; PRAVASTATIN; SIMVASTATIN;

ANENCEPHALUS; ANUS ATRESIA; AORTA ARCH ANOMALY; AORTA COARCTATION; ATRIOVENTRICULAR CANAL; BICUSPID AORTIC VALVE; BIRTH DEFECT; BODY MASS; CHORDEE; CLEFT ALVEOLAR RIDGE; CLEFT LIP; CLEFT LIP PALATE; CRANIOFACIAL SYNOSTOSIS; CRANIORACHISCHISIS; DIABETES MELLITUS; DRUG EXPOSURE; ENVIRONMENTAL EXPOSURE; ESOPHAGUS ATRESIA; FETUS DEATH; FETUS RISK; HEART ATRIUM SEPTUM DEFECT; HEART HYPERTROPHY; HEART LEFT VENTRICLE DOUBLE INLET; HEART SINGLE VENTRICLE; HEART VENTRICLE SEPTUM ANEURYSM; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYDROCEPHALUS; HYPOSPADIAS; LETTER; LIVE BIRTH; MESOCARDIA; MITRAL VALVE REGURGITATION; OBESITY; OCCULT SPINAL DYSRAPHISM; OMPHALOCELE; PATENT DUCTUS ARTERIOSUS; PATENT FORAMEN OVALE; PERSISTENT LEFT PULMONARY ARTERY STENOSIS; PERSISTENT PULMONARY HYPERTENSION; PHENOTYPE; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PULMONARY ARTERY STENOSIS; PULMONARY VALVE STENOSIS; RECTOVAGINAL FISTULA; SACRUM AGENESIS; SIDE EFFECT; TERATOGENICITY; THUMB MALFORMATION; TOE MALFORMATION; TRACHEOESOPHAGEAL FISTULA; TRICUSPID VALVE REGURGITATION; TRISOMY 21;

ABNORMALITIES, DRUG-INDUCED; CASE-CONTROL STUDIES; FEMALE; FETAL DEVELOPMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFANT, NEWBORN; PREGNANCY; PREGNANCY OUTCOME; RISK FACTORS;

EID: 55549094475     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32493     Document Type: Letter

References (26)

1. Becerra JE, Khoury MJ, Cordero JF, Erickson JD. 1990. Diabetes mellitus during pregnancy and the risks for specific birth defects: A population-based case-control study. Pediatrics 85:1-9.
2. Carey JC. 2008. Where observation is concerned, chance favors only the prepared mind. Obstet Gynecol 111:479-480.
3. Collins P, Olufs R, Karvitz H, Babakitis M. 1977. Relationship of maternal warfarin therapy in pregnancy to chondrodysplasia punctata: Report of a case. Am J Obstet Gynecol 127:444-446.
4. Edison RJ, Muenke M. 2004a. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 350:1579-1582.
5. Edison RJ, Muenke M. 2004b. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet Part A 131A:287-298.
6. Edison RJ, Muenke M. 2005. Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly. N Engl J Med 352:2759.
7. Gibb H, Scialli AR. 2005. Statin drugs and congenital anomalies. Am J Med Genet Part A 135A:230-231.
8. Lopez-Rangel E, Van Allen MI. 2005. Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 73:919-923.
9. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683.
10. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. 1996. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 10:439-446.
11. Maron DJ, Fazio S, Linton MF. 2000. Current perspectives on statins. Circulation 101:207-213.
12. Mitchell AA, Rosenberg L, Shapiro S, Slone D. 1981. Birth defects related to bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA 245:2311-2314.
13. Moore LL, Singer MR, Bradlee ML, Rothman KJ, Milunsky A. 2000. Aprospective study of the risk of congenital defects associated with maternal obesity and diabetes mellitus. Epidemiology 11:689-694.
14. National Cholesterol Education Program. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497.
15. Pauli RM, Madden JD, Kranzler KJ, Culpepper W, Port R. 1976. Warfarin therapy initiated during pregnancy and phenotypic chondrodysplasia punctata. J Pediatr 88:506-508.
16. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. 2005. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 73:888-896.
17. Reprotox. 2008. Available at: http:reprotox.org. Accessed May 7, 2008.
18. Shaul WL, Emery H, Hall JG. 1975. Chondrodysplasia punctata and maternal warfarin use during pregnancy. Am J Dis Child 129:360-362.
19. Shaw GM, Velie EM, Schaffer D. 1996. Risk of neural tube defect-affected pregnancies among obese women. JAMA 275:1093-1096.
20. Shepard TH. 1991. Editorial reply to "Comments on 'Moebius syndrome: Animal model - Human correlations and evidence for a brainstem vascular etiology'": Case observation vs. epidemiology studies. Teratology 43:559-560.
21. TERIS (Teratogen Information System). 2008. Available at: http://depts.washington.edu/~terisweb/teris/. Accessed May 8, 2008.
22. Waller DK, Mills JL, Simpson JL, Cunningham GC, Conley MR, Lassman MR, Rhoads GG. 1994. Are obese women at higher risk for producing malformed offspring? Am J Obstet Gynecol 170:541-548.
23. Waller DK, Shaw GM, Rasmussen SA, Hobbs CA, Canfield MA, Siega-Riz AM, Gallaway MS, Correa A. 2007. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 161:745-750.
24. Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. 1996. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology 7:507-512.
25. Werler MM, Louik C, Shapiro S, Mitchell AA. 1996. Prepregnant weight in relation to risk of neural tube defects. JAMA 275:1089-1092.
26. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL, Costa P, Druschel C, Hobbs CA, Romitti PA, Langlois PH, Edmonds LD. 2001. The National Birth Defects Prevention Study. Public Health Rep 116:32-40.